Viridian Therapeutics, Inc. Common Stock (VRDN)

Price$15.78

Value ScoreD

Growth ScoreA

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-58.55%

Price vs S&P 500 (4W)-4.99%

VGM Score52.57

Market Capitalization$1.81B

All Metrics

Book Value / Share (Quarterly)$6.21

P/TBV (Annual)2.17x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)242.07%

Cash Flow / Share (Quarterly)$-2.97

Price vs S&P 500 (YTD)-57.45%

Gross Margin (TTM)2.36%

Net Profit Margin (TTM)-508.46%

EPS (TTM)$-3.96

10-Day Avg Trading Volume1.62M

EPS Excl Extra (TTM)$-3.96

Revenue Growth (5Y)132.18%

EPS (Annual)$-4.04

ROI (Annual)-42.49%

Gross Margin (Annual)2.76%

Net Profit Margin (5Y Avg)-35120.44%

Cash / Share (Quarterly)$7.44

Revenue Growth QoQ (YoY)95.83%

ROA (Last FY)-38.09%

Revenue Growth TTM (YoY)23382.78%

EBITD / Share (TTM)$-4.28

ROE (5Y Avg)-43.32%

Operating Margin (TTM)-543.86%

Cash Flow / Share (Annual)$-2.72

P/B Ratio2.84x

P/B Ratio (Quarterly)3.15x

Net Income / Employee (Annual)$-1,359,500

EV / Revenue (TTM)24.19x

Net Interest Coverage (TTM)-324.65x

ROA (TTM)-50.65%

EPS Incl Extra (Annual)$-4.04

Current Ratio (Annual)12.65x

Quick Ratio (Quarterly)14.71x

3-Month Avg Trading Volume2.40M

52-Week Price Return10.81%

Revenue / Employee (TTM)$281,400

Tangible BV / Share (Quarterly)$6.49

P/S Ratio (Annual)25.48x

Asset Turnover (Annual)0.08x

52-Week High$34.29

Operating Margin (5Y Avg)-38169.46%

EPS Excl Extra (Annual)$-4.04

CapEx CAGR (5Y)65.39%

Tangible BV CAGR (5Y)59.30%

26-Week Price Return-50.63%

Quick Ratio (Annual)12.37x

13-Week Price Return-45.38%

Total Debt / Equity (Annual)0.12x

Current Ratio (Quarterly)15.15x

Enterprise Value$1.72B

Revenue / Share Growth (5Y)23.16%

Asset Turnover (TTM)0.10x

Book Value / Share Growth (5Y)-24.33%

Revenue / Employee (Annual)$281,100

Inventory Turnover (Annual)12.35x

Pretax Margin (Annual)-483.57%

Cash / Share (Annual)$8.59

3-Month Return Std Dev115.93%

Gross Margin (5Y Avg)13.95%

Net Income / Employee (TTM)$-1,430,900

ROE (Last FY)-47.44%

Net Interest Coverage (Annual)-334.48x

EPS Basic Excl Extra (Annual)$-4.04

Receivables Turnover (TTM)2.02x

Total Debt / Equity (Quarterly)0.14x

EPS Incl Extra (TTM)$-3.96

Receivables Turnover (Annual)5.92x

ROI (TTM)-55.72%

P/S Ratio (TTM)25.46x

Pretax Margin (5Y Avg)-35120.44%

Revenue / Share (Annual)$0.84

Tangible BV / Share (Annual)$9.56

Price vs S&P 500 (52W)-13.55%

Year-to-Date Return-49.29%

5-Day Price Return-6.96%

EPS Normalized (Annual)$-4.04

ROA (5Y Avg)-38.35%

Net Profit Margin (Annual)-483.57%

Month-to-Date Return-10.44%

Cash Flow / Share (TTM)$-5.09

EBITD / Share (Annual)$-4.28

Operating Margin (Annual)-512.91%

LT Debt / Equity (Annual)0.12x

ROI (5Y Avg)-41.54%

LT Debt / Equity (Quarterly)0.14x

EPS Basic Excl Extra (TTM)$-3.96

P/TBV (Quarterly)3.02x

P/B Ratio (Annual)4.11x

Inventory Turnover (TTM)12.40x

Pretax Margin (TTM)-508.46%

Book Value / Share (Annual)$7.09

Price vs S&P 500 (13W)-53.63%

Beta0.94x

Revenue / Share (TTM)$0.69

ROE (TTM)-60.70%

52-Week Low$13.18

vGradeD

gGradeA

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.90est. -1.12

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.24

4.21

4.26

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
VRDNViridian Therapeutics, Inc. Common Stock	D	A	D	$15.78
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing therapies for thyroid eye disease. Its lead candidate, Veligrotug, is a humanized monoclonal antibody targeting IGF-1R, available in both intravenous and subcutaneous formulations.